| 1 |
Ferreiro-iglesias R, Piqueras M, Ricart E, Sempere L, Roca M, Martín de Carpi J, Bentitez O, Zabana Y, Mañosa M, Rodríguez-moranta F, Barreiro-de Acosta M. Recommendations of the Spanish Group on Crohn’s Disease and Ulcerative Colitis on the importance, screening and vaccination in inflammatory bowel Disease patients. Gastroenterología y Hepatología (English Edition) 2022. [DOI: 10.1016/j.gastre.2022.03.004] [Reference Citation Analysis]
|
| 2 |
Camus P, Colby TV. The Spectrum of Airway Involvement in Inflammatory Bowel Disease. Clinics in Chest Medicine 2022;43:141-55. [DOI: 10.1016/j.ccm.2021.12.003] [Reference Citation Analysis]
|
| 3 |
Barišić N, Turudić D, Marić LS, Tešović G. Vaccination in pediatric acquired inflammatory immune-mediated neuromuscular disorders. Eur J Paediatr Neurol 2022;36:159-76. [PMID: 34998097 DOI: 10.1016/j.ejpn.2021.12.014] [Reference Citation Analysis]
|
| 4 |
Kucharzik T, Ellul P, Greuter T, Rahier JF, Verstockt B, Abreu C, Albuquerque A, Allocca M, Esteve M, Farraye FA, Gordon H, Karmiris K, Kopylov U, Kirchgesner J, MacMahon E, Magro F, Maaser C, de Ridder L, Taxonera C, Toruner M, Tremblay L, Scharl M, Viget N, Zabana Y, Vavricka S. ECCO Guidelines on the Prevention, Diagnosis, and Management of Infections in Inflammatory Bowel Disease. J Crohns Colitis 2021;15:879-913. [PMID: 33730753 DOI: 10.1093/ecco-jcc/jjab052] [Cited by in Crossref: 81] [Cited by in F6Publishing: 76] [Article Influence: 40.5] [Reference Citation Analysis]
|
| 5 |
Voet M, Calon T, Hendriks M, Schreuder RM. Severe Complication of Thiopurine Treatment in a Young Woman with Crohn's Disease. Eur J Case Rep Intern Med 2021;8:002350. [PMID: 33869095 DOI: 10.12890/2021_002350] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 6 |
Jappe U, Beckert H, Bergmann KC, Gülsen A, Klimek L, Philipp S, Pickert J, Rauber-Ellinghaus MM, Renz H, Taube C, Treudler R, Wagenmann M, Werfel T, Worm M, Zuberbier T. Biologics for atopic diseases: Indication, side effect management, and new developments. Allergol Select 2021;5:1-25. [PMID: 33426426 DOI: 10.5414/ALX02197E] [Cited by in Crossref: 6] [Cited by in F6Publishing: 8] [Article Influence: 3.0] [Reference Citation Analysis]
|
| 7 |
Yamamoto-furusho J, Bosques-padilla F, Martínez-vázquez M. Segundo Consenso Mexicano de terapia biológica y moléculas pequeñas en enfermedad inflamatoria intestinal. Revista de Gastroenterología de México 2021;86:70-85. [DOI: 10.1016/j.rgmx.2020.10.001] [Reference Citation Analysis]
|
| 8 |
Yamamoto-furusho J, Bosques-padilla F, Martínez-vázquez M. Second Mexican consensus on biologic therapy and small-molecule inhibitors in inflammatory bowel disease. Revista de Gastroenterología de México (English Edition) 2021;86:70-85. [DOI: 10.1016/j.rgmxen.2020.10.007] [Reference Citation Analysis]
|
| 9 |
Trivedi A, Katelaris C. The use of biologic agents in the management of uveitis. Intern Med J 2019;49:1352-63. [PMID: 30582273 DOI: 10.1111/imj.14215] [Cited by in Crossref: 22] [Cited by in F6Publishing: 25] [Article Influence: 7.3] [Reference Citation Analysis]
|
| 10 |
Lai HC, Chang CH, Cheng KS, Chen TW, Tsai YY, Chou JW. QuantiFERON-TB Gold Test Conversion Is Associated with Active Tuberculosis Development in Inflammatory Bowel Disease Patients Treated with Biological Agents: An Experience of a Medical Center in Taiwan. Gastroenterol Res Pract 2019;2019:7132875. [PMID: 31781198 DOI: 10.1155/2019/7132875] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 11 |
Cohen SR, Pona A, Cline AE, Feldman SR. The complexity of adverse event assessment and counseling for patients on biologic treatment. Expert Rev Clin Immunol 2019;15:809-11. [PMID: 31290340 DOI: 10.1080/1744666X.2019.1642749] [Reference Citation Analysis]
|
| 12 |
Patel PR, Pittner AC, Merrill PT. Undiagnosed Ocular Syphilis Treated With Immunosuppressive Therapy. Journal of VitreoRetinal Diseases 2019;3:242-245. [DOI: 10.1177/2474126419849200] [Reference Citation Analysis]
|
| 13 |
Click B, Regueiro M. A Practical Guide to the Safety and Monitoring of New IBD Therapies. Inflamm Bowel Dis 2019;25:831-42. [PMID: 30312391 DOI: 10.1093/ibd/izy313] [Cited by in Crossref: 24] [Cited by in F6Publishing: 21] [Article Influence: 6.0] [Reference Citation Analysis]
|
| 14 |
Bezzio C, Imperatore N, Armuzzi A, Rizzello F, Manes G, Bossa F, Calabrese E, Caprioli F, Daperno M, Mocciaro F, Orlando A, Papi C, Rispo A, Saibeni S; the Italian Group for Inflammatory Bowel Disease (IG‐IBD). Barriers to anti‐TNFalpha prescription among Italian physicians managing inflammatory bowel disease. GastroHep 2019;1:93-9. [DOI: 10.1002/ygh2.331] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
|
| 15 |
Murdaca G, Negrini S, Pellecchio M, Greco M, Schiavi C, Giusti F, Puppo F. Update upon the infection risk in patients receiving TNF alpha inhibitors. Expert Opinion on Drug Safety 2019;18:219-29. [DOI: 10.1080/14740338.2019.1577817] [Cited by in Crossref: 23] [Cited by in F6Publishing: 21] [Article Influence: 5.8] [Reference Citation Analysis]
|
| 16 |
Fernández-Ruiz M, Aguado JM. Risk of infection associated with anti-TNF-α therapy. Expert Rev Anti Infect Ther 2018;16:939-56. [PMID: 30388900 DOI: 10.1080/14787210.2018.1544490] [Cited by in Crossref: 35] [Cited by in F6Publishing: 26] [Article Influence: 7.0] [Reference Citation Analysis]
|
| 17 |
Gilhus NE, Romi F, Hong Y, Skeie GO. Myasthenia gravis and infectious disease. J Neurol 2018;265:1251-8. [DOI: 10.1007/s00415-018-8751-9] [Cited by in Crossref: 55] [Cited by in F6Publishing: 62] [Article Influence: 11.0] [Reference Citation Analysis]
|
